Tabletting: the issues facing today's manufacturers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tabletting: the issues facing today's manufacturers

Pharmaceutical Technology Europe
Volume 22, Issue 6

The full version of this tabletting feature can be read in the June issue of our digital magazine: http://www.pharmtech.com/ptedigital0610


(TEK IMAGE/SPL/Getty Images)
Compressed tablets are the most popular solid dosage form and, despite having been used for many years, still offer numerous advantages. For instance, they are portable and very simple to use, and can protect unstable medications or disguise unpalatable ingredients. Importantly, the techniques and equipment required to manufacture compressed tablets are very well established, making the process relatively straightforward. Tablets can be manufactured in almost any size, shape and colour, and breakthroughs made over the years have allowed more complex tablets to be manufactured, such as sustained release or fast dissolving formulations, without the need to change current processes and equipment.


Figure 1
The maturity of tabletting technologies was highlighted in a recent PTE survey, where most respondents indicated that tablet manufacture problems could usually be traced back to poor formulation design rather than problems with manufacturing equipment (Figure 1).

As tabletting is so crucial to the pharma industry, we have dedicated this month's special feature to tabletting processes and technologies. Unlike some industries we have studied that have witnessed many innovations in recent years, the tablet manufacturing industry has remained relatively static and still utilises the same methods and technologies that have been around for many years, although in many cases improvements have been made to boost throughput and increase machine flexibility and efficiency.

Although there have been few major innovations, however, this doesn't mean that the industry is not evolving. The sector is seeing a shift in processing methodology as companies seek to implement Quality by Design principles and there is also a growing emphasis on generics. Additionally, the threat of falsified medicines has necessitated the need for coding and identification technologies, as well as sophisticated analytical methods that can distinguish between genuine and counterfeit products.

To find out about the current state of tablet manufacture, PTE spoke to several experts involved in the manufacturing process, including granulation, drying and equipment troubleshooting.

Our full special feature of tabletting technologies, featuring contributions on the subjects of blending, coating, tablet analysis and more, as well as a product showcase of some of the latest equipment and systems, can be accessed at: http://www.pharmtech.com/ptedigital0610/

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here